Condition
T-cell Prolymphocytic Leukemia clinical trials and research
As of November 12, 2026, Find a Trial lists 6 T-cell Prolymphocytic Leukemia clinical trials that are recruiting, at sites in 2 countries (most in United States (5), China (1)). By phase: Phase 1/2 (3), Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 2Countries
Newest T-cell Prolymphocytic Leukemia clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma | Phase 2 | Columbus, Ohio and 1 other locations | Recruiting | Jan 21, 2026 |
| Combination therapy with ruxolitinib, cladribine, and venetoclax in relapsed/refractory T-cell prolymphocytic leukemia | Phase 1/2 | Houston, Texas | Recruiting | Dec 31, 2025 |
| Duvelisib plus venetoclax for relapsed or refractory peripheral T‑cell lymphoma | Phase 1/2 | Los Angeles, California | Recruiting | Feb 6, 2025 |
| CAR-T cell therapy targeting CD5 and CD7 for T-cell leukemia and lymphoma | Phase 1/2 | Beijing, Beijing Municipality | Recruiting | May 17, 2024 |
| Registry for individuals with T-cell lymphoma | — | Duarte, California and 25 other locations | Recruiting | Aug 7, 2023 |
| Oral treatment with LP-118 for patients with various blood cancers | Phase 1 | Chicago, Illinois and 7 other locations | Recruiting | Feb 25, 2021 |
All recruiting trials (6)
-
Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma
This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.
-
Combination therapy with ruxolitinib, cladribine, and venetoclax in relapsed/refractory T-cell prolymphocytic leukemia
This study tests whether a three-drug combo can control relapsed or refractory T-PLL in adults.
-
Duvelisib plus venetoclax for relapsed or refractory peripheral T‑cell lymphoma
This trial tests whether combining duvelisib and venetoclax can help people with relapsed or refractory peripheral T‑cell lymphoma.
-
CAR-T cell therapy targeting CD5 and CD7 for T-cell leukemia and lymphoma
This study is testing a new CAR-T cell therapy for young people with tough-to-treat T-cell leukemia and lymphoma to see if it can help them when other treatments haven't worked.
-
Registry for individuals with T-cell lymphoma
This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.
-
Oral treatment with LP-118 for patients with various blood cancers
This study is testing a new oral treatment called LP-118 to see if it is safe and can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.
Related topics
Quick answers
How many T-cell Prolymphocytic Leukemia clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (5 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3, Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.